GlassScriptPhysician profile
Mona Alqulali
NPI 1497722979
$3,547.34
in general payments reported to CMS, 2019-2025
25 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,256 · 2020: $84.62 · 2021: $238 · 2022: $458 · 2023: $101 · 2024: $183 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $417 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.94 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,829.66 | 2019 | |
| Abbvie INC. | $324.82 | 2019-2025 | |
| Novo Nordisk INC | $237.52 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $198.56 | 2019-2024 | Farxiga |
| Astellas Pharma US INC | $149.63 | 2022-2024 | Veozah |
| Lilly USA, LLC | $139.03 | 2019-2022 | |
| Hologic Sales and Service, LLC | $91.66 | 2025 | Novasure |
| Bayer Healthcare Pharmaceuticals INC. | $88.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $62.84 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $59.26 | 2019-2023 | Gattex |
| Alydia Health | $57.01 | 2021 | |
| Medtronic, INC. | $51.59 | 2022 | |
| Upsher-Smith Laboratories LLC | $34.21 | 2019 | |
| Davol INC. | $32.86 | 2025 | Galaflex |
| Lupin INC. | $30.04 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $19.23 | 2021 | |
| Abbott Laboratories | $18.32 | 2024 | Freestyle Libre 3 |
| Myovant Sciences INC. | $18.25 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.23 | 2021 | |
| Amgen INC. | $15.70 | 2024 | Otezla, Repatha |
| Shire North American Group INC | $15.10 | 2019 | |
| Pfizer INC. | $14.34 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.33 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.39 | 2022 | |
| Channel Medsystems, INC. | $12.79 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Alqulali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.